Eric Legius

Professor Eric Legius is a Professor of Medicine in the Department of Human Genetics at KU Leuven, Belgium. He specializes in genetics, neurofibromatosis research, and molecular biology, contributing to advancements in the understanding of tumor pathogenesis, microdeletions, and genetic syndromes.

Professor Legius leads the Laboratory for Neurofibromatosis Research at KU Leuven, where he investigates the molecular mechanisms underlying neurofibromatosis type 1 (NF1), Legius syndrome, and pseudarthrosis. His research focuses on the RAS pathway and its role in genetic disorders, exploring how mutations in key genes contribute to tumor development and skeletal abnormalities.

His contributions to neurofibromatosis research have helped refine diagnostic criteria and treatment approaches for patients with NF1 and Legius syndrome. He has co-authored studies on genetic mutations affecting the SPRED1 gene, providing insights into the molecular basis of Legius syndrome and its clinical manifestations. His work has been instrumental in distinguishing Legius syndrome from NF1, ensuring accurate diagnoses and targeted interventions.

Beyond his research, Professor Legius is actively involved in medical education, mentoring students and healthcare professionals in clinical genetics and molecular medicine. He is a member of the KU Leuven Cancer Institute (LKI) and contributes to multidisciplinary collaborations aimed at improving patient care for individuals with genetic disorders.

He has published extensively in peer-reviewed journals, advancing knowledge in tumor genetics, skeletal abnormalities, and neurofibromatosis-related conditions. His research continues to shape genetic medicine, providing valuable insights into the molecular mechanisms driving hereditary diseases.

‍